Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin (LUNG-NEPA)
A Standard Regimen of Dexamethasone in Comparison to Two Dex-sparing Regimens in Addition to NEPA in Preventing CINV in naïve NSCLC Patients to be Treated With Cisplatin Based Chemotherapy: a Three-arm, Open-label, Randomized Study
Sponsor: Consorzio Oncotech
Listed as NCT04201769, this PHASE3 trial focuses on Chemotherapy-induced Nausea and Vomiting and remains ongoing. Sponsored by Consorzio Oncotech, it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
May 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — May 2022 [monthly]
Active Not Recruiting PHASE3
▶ Show 2 earlier versions
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2020 — May 2020 [monthly]
Recruiting PHASE3
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Consorzio Oncotech
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bari, Italy , Brescia, Italy , Cosenza, Italy , Feltre, Italy , Lecco, Italy , Legnano, Italy , Modena, Italy , Monza, Italy , Napoli, Italy , Orbassano, Italy and 11 more locations